Literature DB >> 20215412

Transmembrane segment five serines of the D4 dopamine receptor uniquely influence the interactions of dopamine, norepinephrine, and Ro10-4548.

David F Cummings1, Spencer S Ericksen, Angela Goetz, John A Schetz.   

Abstract

Conserved serines of transmembrane segment (TM) five (TM5) are critical for the interactions of endogenous catecholamines with alpha(1)- and alpha(2)-adrenergic, beta(2)-adrenergic, and D1, D2, and D3 dopamine receptors. The unique high-affinity interaction of the D4 dopamine receptor subtype with both norepinephrine and dopamine, and the fact that TM5 serine interactions have never been studied for this receptor subtype, led us to investigate the interactions of ligands with D4 receptor TM5 serines. Serine-to-alanine mutations at positions 5.42 and 5.46 drastically decreased affinities of dopamine and norepinephrine for the D4 receptor. The D4-S5.43A receptor mutant had substantially reduced affinity for norepinephrine, but a modest loss of affinity for dopamine. In functional assays of cAMP accumulation, norephinephrine was unable to activate any of the mutant receptors, even though the agonist quinpirole displayed wild-type functional properties for all of them. Dopamine was unable to activate the S5.46A mutant and had reduced potency for the S5.43A mutant and reduced potency and efficacy for the S5.42A mutant. In contrast, Ro10-4548 [RAC-2'-2-hydroxy-3-4-(4-hydroxy-2-methoxyphenyl)-1-piperazinyl-propoxy-acetanilide], a catechol-like antagonist of the wild-type receptor unexpectedly functions as an agonist of the S5.43A mutant. Other noncatechol ligands had similar properties for mutant and wild-type receptors. This is the first example of a dopamine receptor point mutation selectively changing the receptor's interaction with a specific antagonist to that of an agonist, and together with other data, provides evidence, supported by molecular modeling, that catecholamine-type agonism is induced by different ligand-specific configurations of intermolecular H-bonds with the TM5 conserved serines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20215412      PMCID: PMC2879936          DOI: 10.1124/jpet.109.164962

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists.

Authors:  C D Strader; M R Candelore; W S Hill; R A Dixon; I S Sigal
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

2.  Study of interaction between agonists and asn293 in helix VI of human beta(2)-adrenergic receptor.

Authors:  H M Zuurmond; J Hessling; K Blüml; M Lohse; A P Ijzerman
Journal:  Mol Pharmacol       Date:  1999-11       Impact factor: 4.436

3.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

4.  Dysfunctional light-evoked regulation of cAMP in photoreceptors and abnormal retinal adaptation in mice lacking dopamine D4 receptors.

Authors:  Izhak Nir; Joseph M Harrison; Rashidul Haque; Malcolm J Low; David K Grandy; Marcelo Rubinstein; P Michael Iuvone
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

5.  Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor.

Authors:  Juha M Peltonen; Tommi Nyrönen; Siegfried Wurster; Marjo Pihlavisto; Anna-Marja Hoffrén; Anne Marjamäki; Henri Xhaard; Liisa Kanerva; Juha-Matti Savola; Mark S Johnson; Mika Scheinin
Journal:  Br J Pharmacol       Date:  2003-08-18       Impact factor: 8.739

6.  Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states.

Authors:  Gayathri Swaminath; Yang Xiang; Tae Weon Lee; Jacqueline Steenhuis; Charles Parnot; Brian K Kobilka
Journal:  J Biol Chem       Date:  2003-10-14       Impact factor: 5.157

7.  Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the beta2 adrenergic receptor.

Authors:  George Liapakis; Wai Chi Chan; Maria Papadokostaki; Jonathan A Javitch
Journal:  Mol Pharmacol       Date:  2004-05       Impact factor: 4.436

8.  Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.

Authors:  Marlon Cowart; Steven P Latshaw; Pramila Bhatia; Jerome F Daanen; Jeffrey Rohde; Sherry L Nelson; Meena Patel; Teodozyi Kolasa; Masaki Nakane; Marie E Uchic; Loan N Miller; Marc A Terranova; Renjie Chang; Diana L Donnelly-Roberts; Marian T Namovic; Peter R Hollingsworth; Brenda R Martino; James J Lynch; James P Sullivan; Gin C Hsieh; Robert B Moreland; Jorge D Brioni; Andrew O Stewart
Journal:  J Med Chem       Date:  2004-07-15       Impact factor: 7.446

9.  Pharmacological and functional characterisation of dopamine D4 receptors in the rat retina.

Authors:  Smita Patel; Kerry L Chapman; Deborah Marston; Peter H Hutson; C Ian Ragan
Journal:  Neuropharmacology       Date:  2003-06       Impact factor: 5.250

10.  "Induced-fit" mechanism for catecholamine binding to the beta2-adrenergic receptor.

Authors:  Renata Del Carmine; Paola Molinari; Maria Sbraccia; Caterina Ambrosio; Tommaso Costa
Journal:  Mol Pharmacol       Date:  2004-08       Impact factor: 4.436

View more
  10 in total

1.  Norepinephrine activates dopamine D4 receptors in the rat lateral habenula.

Authors:  David H Root; Alexander F Hoffman; Cameron H Good; Shiliang Zhang; Eduardo Gigante; Carl R Lupica; Marisela Morales
Journal:  J Neurosci       Date:  2015-02-25       Impact factor: 6.167

Review 2.  Norepinephrine at the nexus of arousal, motivation and relapse.

Authors:  Rodrigo A España; Brooke E Schmeichel; Craig W Berridge
Journal:  Brain Res       Date:  2016-01-07       Impact factor: 3.252

3.  Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.

Authors:  Clinton E Canal; Tania Cordova-Sintjago; Yue Liu; Myong S Kim; Drake Morgan; Raymond G Booth
Journal:  J Pharmacol Exp Ther       Date:  2013-09-30       Impact factor: 4.030

4.  Ring substituents on substituted benzamide ligands indirectly mediate interactions with position 7.39 of transmembrane helix 7 of the D4 dopamine receptor.

Authors:  Spencer S Ericksen; David F Cummings; Michael E Teer; Shahnawaz Amdani; John A Schetz
Journal:  J Pharmacol Exp Ther       Date:  2012-05-15       Impact factor: 4.030

5.  Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-Like Receptor Agonist.

Authors:  Marta Sánchez-Soto; Alessandro Bonifazi; Ning Sheng Cai; Michael P Ellenberger; Amy Hauck Newman; Sergi Ferré; Hideaki Yano
Journal:  Mol Pharmacol       Date:  2016-02-03       Impact factor: 4.436

6.  Ligand-directed bias of G protein signaling at the dopamine D2 receptor.

Authors:  Ee Von Moo; Kasper Harpsøe; Alexander S Hauser; Ikuo Masuho; Hans Bräuner-Osborne; David E Gloriam; Kirill A Martemyanov
Journal:  Cell Chem Biol       Date:  2021-07-23       Impact factor: 8.116

7.  Agonist binding by the β2-adrenergic receptor: an effect of receptor conformation on ligand association-dissociation characteristics.

Authors:  Anita Plazinska; Wojciech Plazinski; Krzysztof Jozwiak
Journal:  Eur Biophys J       Date:  2015-03-01       Impact factor: 1.733

8.  Evolution of dopamine receptors: phylogenetic evidence suggests a later origin of the DRD2l and DRD4rs dopamine receptor gene lineages.

Authors:  Juan C Opazo; Kattina Zavala; Soledad Miranda-Rottmann; Roberto Araya
Journal:  PeerJ       Date:  2018-04-13       Impact factor: 2.984

Review 9.  Functional and pharmacological role of the dopamine D4 receptor and its polymorphic variants.

Authors:  Sergi Ferré; Annabelle M Belcher; Jordi Bonaventura; César Quiroz; Marta Sánchez-Soto; Verònica Casadó-Anguera; Ning-Sheng Cai; Estefanía Moreno; Comfort A Boateng; Thomas M Keck; Benjamín Florán; Christopher J Earley; Francisco Ciruela; Vicent Casadó; Marcelo Rubinstein; Nora D Volkow
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

10.  The Significance of Halogen Bonding in Ligand-Receptor Interactions: The Lesson Learned from Molecular Dynamic Simulations of the D4 Receptor.

Authors:  Rafał Kurczab; Katarzyna Kucwaj-Brysz; Paweł Śliwa
Journal:  Molecules       Date:  2019-12-25       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.